Fujirebio Obtains Manufacturing and Sales Approval for Cancer Gene Testing System 'Fujinokuni HOPE OncoPanel'
NQ Score
48/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Fujirebio Inc., part of the H.U. Group, obtained regulatory approval for 'Fujinokuni HOPE OncoPanel,' a cancer genome profiling program. Developed based on data from 5,143 Japanese patients in collaboration with Shizuoka Cancer Center and SRL, this system enables precise diagnosis and personalized treatment by analyzing 410 cancer-related genes.